Consilium MedicumConsilium MedicumConsilium MedicumConsilium Medicum2075-17532542-2170Consilium Medicum94101ArticlesСтатьиResearch ArticleTadalafil v lechenii simptomov so storony nizhnikh mochevykh putey: obzor literatury i sushchestvuyushchey klinicheskoy praktiki v RossiiТадалафил в лечении симптомов со стороны нижних мочевых путей: обзор литературы и существующей клинической практики в РоссииGovorovA. VГоворовА. В

Кафедра урологии

KasyanG. RКасянГ. Р

Кафедра урологии

Vasil'evA. OВасильевА. О

Кафедра урологии

Pushkar'D. YuПушкарьД. Ю

Кафедра урологии

ГБОУ ВПО Московский государственный медико-стоматологический университет им. А.И.Евдокимова Минздрава России15072014167VOL 16, NO7 (2014)ТОМ 16, №7 (2014)334128122021Copyright ©; 2014, Consilium MedicumCopyright ©; 2014, ООО "Консилиум Медикум"2014Consilium MedicumООО "Консилиум Медикум"https://creativecommons.org/licenses/by-nc-sa/4.0https://consilium.orscience.ru/2075-1753/article/view/94101

В целом и эректильная дисфункция (ЭД), и симптомы нижних мочевых путей (СНМП), обусловленные доброкачественной гиперплазией предстательной железы (ДГПЖ), часто встречаются у мужчин, при этом частота обоих заболеваний с возрастом увеличивается. Клиническая практика, связанная с терапией СНМП/ДГПЖ в России, отражает применение традиционной лекарственной терапии, представленной в руководстве EAU и других руководствах, а также видов лечения, специфических для российских условий. Несмотря на отсутствие научно обоснованных доказательств, фитотерапия и пищевые добавки представляют собой часто рекомендуемый вид лечения среди врачей и фармацевтов в России. Причина данного явления сложная и включает в себя воздействие агрессивной рекламы со стороны производителей и недостаточную финансовую поддержку со стороны государства для отдельных категорий пациентов с низким уровнем дохода. С учетом имеющейся на сегодняшний день распространенности СНМП, вызванных ДГПЖ, у мужчин среднего и пожилого возраста в России явно существуют нереализованные потребности в лечении, которые не могут быть удовлетворены применяющимися в настоящий момент видами терапии. В качестве единственного ингибитора ФДЭ-5, в настоящее время зарегистрированного для лечения СНМП у мужчин с ДГПЖ, тадалафил представляет собой средство, которое можно применять либо в виде монотерапии, либо в комбинации с традиционными препаратами в основном у мужчин, страдающих и СНМП/ДГПЖ, и ЭД. В настоящее время постоянно увеличивается количество доказательств того, что тадалафил способствует независимым клиническим улучшениям при СНМП и ЭД.

Coyne K.S, Sexton C.C, Thompson C.L et al. The prevalence of lower urinary tract symptoms (LUTS) in the USA, the UK and Sweden: results from the Epidemiology of LUTS (EpiLUTS) study. BJU Int 2009; 104: 352-60.Coyne K.S, Sexton C.C, Bell J.A et al. The prevalence of lower urinary tract symptoms (LUTS) and overactive bladder (OAB) by racial/ethnic group and age: Results from OAB-POLL. Neurourol Urodyn 2013; 32: 230-7.Platz E.A, Joshu C.E, Mondul A.M et al. Incidence and progression of lower urinary tract symptoms in a large prospective cohort of United States men. J Urol 2012; 188: 496-501.Prins J, Blanker M.H, Bohnen A.M et al. Prevalence of erectile dysfunction: a systematic review of population - based studies. Int J Impot Res 2002; 14: 422-32.Pushkar D.Y, Kamalov A.A, Al-Shukri S.H et al. An epidemiological study of the prevalence of erectile dysfunction in the Russian Federation. Russ Med J 2012; p. 112.Kubin M, Wagner G, Fugl-Meyer A.R. Epidemiology of erectile dysfunction. Int J Impot Res 2003; 15: 63-71.Seftel A.D, De la Rosette J, Birt J Porter V et al. Coexisting lower urinary tract symptoms and erectile dysfunction: a systematic review of epidemiological data. Int J Clin Pract 2013; 67: 32-45.Ponholzer A, Temml C, Obermayr R, Madersbacher S. Association between lower urinary tract symptoms and erectile dysfunction. Urology 2004; 64: 772-6.Braun M.H, Sommer F, Haupt G et al. Lower urinary tract symptoms and erectile dysfunction: comorbidity or typical «aging male» symptoms? Results of the «Cologne Male Survey». Eur Urol 2003; 44: 588-94.Rosen R, Altwein J, Boyle P et al. Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7). Eur Urol 2003; 44: 637-49.Oelke M, Bachmann A, Descazeaud A et al. M. Guidelines on the management of male lower urinary tract symptoms (LUTS), incl. benign prostatic obstruction (BPO). European Association of Urology 2013. Available from http://www.uroweb.org/gls/pdf/ 13_Male_LUTS_LR.pdfMcVary K.T, Roehrborn C.G, Avins A.L et al. Update on AUA guideline on the management of benign prostatic hyperplasia. J Urol 2011; 185: 1793-803.Cornu J.N, Cussenot O, Haab F, Lukacs B. A widespread population study of actual medical management of lower urinary tract symptoms related to benign prostatic hyperplasia across Europe and beyond official clinical guidelines. Eur Urol 2010; 58: 450-6.Govorov A.V, Pushkar D.Y. The improvement of continence recovery by tadalafil after bilateral nerve - sparing robot - assisted radical prostatectomy: a randomized study with 1 year follow - up. Eur Urol Suppl 2012; 11: e564.P.R. Newswire (Oct. 30, 2012). European Commission approves Cialis® (tadalafil) tablets for the treatment of the signs and symptoms of benign prostatic hyperplasia. Available from http://newsroom.lilly.com/releasedetail.cfm?releaseid=717071. Accessed April 4, 2013Giuliano F, Ückert S, Maggi M et al. The mechanism of action of phosphodiesterase type 5 inhibitors in the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia. Eur Urol 2013; 63: 506-16.Mc Vary K.T. Erectile dysfunction and lower urinary tract symptoms secondary to BPH. Eur Urol 2005; 47: 838-45.Gacci M, Eardley I, Giuliano F et al. Critical analysis of the relationship between sexual dysfunctions and lower urinary tract symptoms due to benign prostatic hyperplasia. Eur Urol 2011; 60: 809-25.Andersson K.E, De Groat W.C, Mc Vary K.T et al. Tadalafil for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: Pathophysiology and mechanism(s) of action. Neurourol Urodyn 2011; 30: 292-301.Kim S.D, Park J.W. Role of phosphodiesterase type 5 inhibitor on benignprostatic hyperplasia/lower urinary tract symptoms. Korean J Androl 2011; 29: 91-100.Yassin A, Saad F, Hoesl C.E et al. Alpha - adrenoceptors are a common denominator in the pathophysiology of erectile function and BPH/LUTS-implications for clinical practice. Andrologia 2006; 38: 1-12.Uckert S, Sormes M, Kedia G et al. Effects of phosphodiesterase inhibitors on tension induced by norepinephrine and accumulation of cyclic nucleotides in isolated human prostatic tissue. Urology 2008; 71: 526-30.Kedia G.T, Sonnenberg J.E, Kuczyk M.A, Uckert S. In vitro functional responses of isolated human urethral tissue to phosphodiesterase (PDE) inhibitors (Abstract 931). Eur Urol Suppl 2011; 10: 291-2.Filippi S, Morelli A, Sandner P et al. Characterization and functional role of androgen - dependent PDE5 activity in the bladder. Endocrinology 2007; 148: 1019-29.Morelli A, Sarchielli E, Comeglio P et al. Phosphodiesterase type 5 expression in human and rat lower urinary tract tissues and the effect of tadalafil on prostate gland oxygenation in spontaneously hypertensive rats. J Sex Med 2011; 8: 2746-60.Azadzoi K.M, Babayan R.K, Kozlowski R, Siroky M.B. Chronic ischemia increases prostatic smooth muscle contraction in the rabbit. J Urol 2003; 170: 659-63.Bertolotto M, Trincia E, Zappetti R et al. Effect of tadalafil on prostate haemodynamics: preliminary evaluation with contrast - enhanced US. Radiol Med 2009; 114: 1106-14.Behr-Roussel D, Oger S, Caisey S et al. Vardenafil decreases bladder afferent nerve activity in unanesthetized, decerebrate, spinal cordinjured rats. Eur Urol 2011; 59: 272-9.Minagawa T, Aizawa N, Igawa Y, Wyndaele JJ. Inhibitory effects of phosphodiesterase 5 inhibitor, tadalafil, on mechanosensitive bladder afferent nerve activities of the rat, and on acrolein - induced hyperactivity of these nerves. BJU Int 2012; 110: E259-66.Gacci M, Salvi M, Sebastianelli A et al. The use of a single daily dose of tadalafil to treat signs and symptoms of benign prostatic hyperplasia and erectile dysfunction. Res Rep Urol 2013; 5: 99-111.Gacci M, Corona G, Salvi M et al. A systematic review and meta - analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with a - blockers for lower urinary tract symptoms due to benign prostatic hyperplasia. Eur Urol 2012; 61: 994-1003.Martínez-Salamanca J.I, Carballido J et al. Phosphodiesterase type 5 inhibitors in the management of non - neurogenic male lower urinary tract symptoms: critical analysis of current evidence. Eur Urol 2011; 60: 527-35.Roehrborn C.G, Mc Vary K.T, Elion-Mboussa A, Viktrup L. Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study. J Urol 2008; 180: 1228-4.American Urological Association (AUA). Guideline on the management of benign prostatic hyperplasia (BPH). AUA Web site. http://www. auanet.org/content/guidelines-and-quality-care/clinical-guidelines/ main-reports/bph-management/chap_1_Guideline Management of (BPH).pdf. Updated 2010. Accessed July 20, 2011Broderick G.A, Brock G.B, Roehrborn C.G et al. Effects of tadalafil on lower urinary tract symptoms secondary to benign prostatic hyperplasia in men with or without erectile dysfunction. Urology 2010;75:1452-8.Donatucci C.F, Brock G.B, Goldfischer E.R et al. Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a 1 year open - label extension study. BJU Int 2011; 107: 1110-6.Porst H, Kim E.D, Casabé A.R et al. LVHJ study team. Efficacy and safety of tadalafil once daily in the treatment of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: results of a multinational randomized, double - blind, placebo - controlled trial. Eur Urol 2011; 60: 1105-13.Egerdie R.B, Auerbach S, Roehrborn et al. Tadalafil 2,5 or 5 mg administered once daily for 12 weeks in men with both erectile dysfunction and signs and symptoms of benign prostatic hyperplasia: results of a randomized, placebo - controlled, double - blind study. J Sex Med 2012; 9: 271-81.Porst H, Oelke M, Goldfischer E.R et al. Efficacy and safety of tadalafil 5 mg once daily for lower urinary tract symptoms suggestive of benign prostatic hyperplasia: subgroup analyses of pooled data from 4 multinational, randomized, placebo - controlled clinical studies. Urology 2013; 82 (3): 667-73.Porst H, Roehrborn C.G, Secrest R.J et al. Effects of tadalafil on lower urinary tract symptoms secondary to benign prostatic hyperplasia and on erectile dysfunction in sexually active men with both conditions: analyses of pooled data from four randomized, placebo - controlled tadalafil clinical studies. J Sex Med 2013; doi: 10.1111/jsm.12212.Brock G, Broderick G, Roehrborn C.G et al. Tadalafil once daily in the treatment of lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH) in men without erectile dysfunction. BJU Int 2013; doi: 10.1111/bju.12251.Oelke M, Giuliano F, Mirone V et al. Monotherapy with tadalafil or tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel, placebo - controlled clinical trial. Eur Urol 2012; 61: 917-25.Giuliano F, Oelke M, Jungwirth A et al. Tadalafil once daily improves ejaculatory function, erectile function, and sexual satisfaction in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia and erectile dysfunction: results from a randomized, placebo - and tamsulosin - controlled, 12-week double - blind study. J Sex Med 2013; 10: 857-65.Kumar S, Kondareddy C, Ganesamoni R et al. Randomized controlled trial to assess the efficacy of the combination therapy of alfuzosin and tadalafil in patients with lower urinary tract symptoms due to benign prostatic hyperplasia. LUTS: Lower urinary tract symptoms. 2013; doi: 10.1111/luts.12016.Regadas R.P, Reges R, Cerqueira J.B et al. Urodynamic effects of the combination of tamsulosin and daily tadalafil in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia: a randomized, placebo - controlled clinical trial. Int Urol Nephrol 2013; 45: 39-43.Bechara A, Romano S, Casabé A et al. Comparative efficacy assessment of tamsulosin vs. tamsulosin plus tadalafil in the treatment of LUTS/BPH. Pilot study. J Sex Med 2008; 5 (9): 2170-8.CIALISR (tadalafil) Prescribing Information. Eli Lilly and Company. Revised October 2011.Miller M.S. Role of phosphodiesterase type 5 inhibitors for lower urinary tract symptoms. Ann Pharmacother 2013; 47: 278-83.Roehrborn C.G, Casabe A.R, Da Pozzo L.F et al. Effects of the once - daily coadministration of tadalafil with finasteride for 6 months: A randomized, placebo - controlled study in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia. 28th Annual European Association of Urology (EAU) Congress; Milan, Italy; Mar 15-19, 2013. Poster 1096.Takeda M, Nishizawa O, Imaoka T et al. LVIA: Tadalafil for the treatment of lower urinary tract symptoms in Japanese men with benign prostatic hyperplasia; results from a 12-week placebo - controlled dose - finding study and a 42-week open - label extension. LUTS 2012; 3: 110-9.Dmochowski R, Roehrborn C, Klise S et al. Urodynamic effects of once daily tadalafil in men with lower urinary tract symptoms secondary to clinical benign prostatic hyperplasia: a randomized, placebo controlled 12-week clinical trial. J Urol 2010; 183: 1092-7.Goldfischer E, Kowalczyk J.J, Clark W.R et al. Hemodynamic effects of once - daily tadalafil in men with signs and symptoms of benign prostatic hyperplasia on concomitant a1-adrenergic antagonist therapy: results of a multicenter randomized, double - blind, placebo - controlled trial. Urology 2012; 79: 875-82.Casabé A, Roehrborn C.G, Da Pozzo L.F et al. Efficacy and safety of the coadministration of tadalafil once daily with finasteride for 6 months in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia. J Urol 2014; 191 (3): 727-33.